만성 골수성 백혈병 치료제 시장(2026-2030년)

The global chronic myelogenous leukemia therapeutics market is forecasted to grow by USD 2237.5 mn during 2025-2030, accelerating at a CAGR of 5.8% during the forecast period. The report on the global chronic myelogenous leukemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in precision oncology and industrialization of stamp inhibitors, strategic shift toward treatment-free remission and enhanced molecular, evolution of geriatric-focused care and demand for targeted low-toxicity.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global chronic myelogenous leukemia therapeutics market is segmented as below:

By Product

• Targeted therapy
• Chemotherapy
• Immunotherapy

By Route Of Administration

• Oral
• Intravenous
• Subcutaneous
• Others

By Type

• First-line
• Second-line
• Third-line and beyond

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the institutionalization of ai-enabled molecular monitoring and precision diagnostics as one of the prime reasons driving the global chronic myelogenous leukemia therapeutics market growth during the next few years. Also, growth of differentiated tyrosine kinase inhibitor and bioavailability and expansion of innate immune system activation and elane pathway targeting will lead to sizable demand in the market.

The report on the global chronic myelogenous leukemia therapeutics market covers the following areas:

• Global chronic myelogenous leukemia therapeutics market sizing
• Global chronic myelogenous leukemia therapeutics market forecast
• Global chronic myelogenous leukemia therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global chronic myelogenous leukemia therapeutics market vendors that include Accord Healthcare Ltd., Apotex Inc., Ascentage Pharma Group Intl., Aurobindo Pharma Ltd., Be One Medicines AG, Bristol Myers Squibb Co., Cipla Inc., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hansoh Pharmaceutical Group Co. Ltd., Hikma Pharmaceuticals Plc, Innovent Biologics Inc., Lupin Ltd., Natco Pharma Ltd., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries, Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Zydus Lifesciences Ltd.. Also, the global chronic myelogenous leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Chronic Myelogenous Leukemia Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Chronic Myelogenous Leukemia Therapeutics Market 2020 - 2024 ($ million)
• 5.2 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ million)
• 5.3 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.4 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI in global chronic myelogenous leukemia therapeutics market
• 6.2 Impact of geopolitical conflict for global chronic myelogenous leukemia therapeutics market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product

• 8.1 Market segments
• 8.2 Comparison by Product
• 8.3 Targeted therapy - Market size and forecast 2025-2030
• 8.4 Chemotherapy - Market size and forecast 2025-2030
• 8.5 Immunotherapy - Market size and forecast 2025-2030
• 8.6 Market opportunity by Product
  • Market opportunity by Product ($ million)

9 Market Segmentation by Route of Administration

• 9.1 Market segments
• 9.2 Comparison by Route of Administration
• 9.3 Oral - Market size and forecast 2025-2030
• 9.4 Intravenous - Market size and forecast 2025-2030
• 9.5 Subcutaneous - Market size and forecast 2025-2030
• 9.6 Others - Market size and forecast 2025-2030
• 9.7 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

10 Market Segmentation by Type

• 10.1 Market segments
• 10.2 Comparison by Type
• 10.3 First-line - Market size and forecast 2025-2030
• 10.4 Second-line - Market size and forecast 2025-2030
• 10.5 Third-line and beyond - Market size and forecast 2025-2030
• 10.6 Market opportunity by Type
  • Market opportunity by Type ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Thailand - Market size and forecast 2025-2030
  • 12.5.6 Indonesia - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 South Africa - Market size and forecast 2025-2030
  • 12.6.4 Argentina - Market size and forecast 2025-2030
  • 12.6.5 Turkey - Market size and forecast 2025-2030
  • 12.6.6 UAE - Market size and forecast 2025-2030
  • 12.6.7 Israel - Market size and forecast 2025-2030
  • 12.6.8 Colombia - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Advancements in precision oncology and industrialization of STAMP inhibitors
  • Strategic shift toward treatment-free remission and enhanced molecular
  • Evolution of geriatric-focused care and demand for targeted low-toxicity
• 13.2 Market challenges
  • Targeted therapy resistance and BCR-ABL genomic complexity
  • Financial burden and global reimbursement framework resistance
  • Treatment adherence struggles and chronic adverse effects
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Institutionalization of AI-enabled molecular monitoring and precision diagnostics
  • Growth of differentiated tyrosine kinase inhibitor and bioavailability
  • Expansion of innate immune system activation and ELANE pathway targeting

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Ascentage Pharma Group Intl.
  • Ascentage Pharma Group Intl. - Overview
  • Ascentage Pharma Group Intl. - Product / Service
  • Ascentage Pharma Group Intl. - Key offerings
  • SWOT
• 15.5 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Product / Service
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • SWOT
• 15.6 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.7 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.8 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.9 Glenmark Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd. - Overview
  • Glenmark Pharmaceuticals Ltd. - Product / Service
  • Glenmark Pharmaceuticals Ltd. - Key news
  • Glenmark Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.10 Hikma Pharmaceuticals Plc
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key news
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Segment focus
  • SWOT
• 15.11 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.12 Natco Pharma Ltd.
  • Natco Pharma Ltd. - Overview
  • Natco Pharma Ltd. - Product / Service
  • Natco Pharma Ltd. - Key news
  • Natco Pharma Ltd. - Key offerings
  • SWOT
• 15.13 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.14 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.15 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.16 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.17 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 Zydus Lifesciences Ltd.
  • Zydus Lifesciences Ltd. - Overview
  • Zydus Lifesciences Ltd. - Business segments
  • Zydus Lifesciences Ltd. - Key news
  • Zydus Lifesciences Ltd. - Key offerings
  • Zydus Lifesciences Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations